Research Program; Initial Term. The Research Program shall commence as soon as practicable after the Effective Date. Subject to the oversight and management of the JSC, ChemoCentryx shall have principal responsibility for the conduct of the Research Program, including all scientific, clinical, and regulatory activities in accordance with the Research Plan described in Section 3.5. GSK shall provide research funding to support activities under the Research Program pursuant to Section 3.7, and consultation and advice with respect to such activities, which shall be considered in good faith by ChemoCentryx. The Research Program will terminate upon the end of the third (3rd) Contract Year (the “Initial Term”), unless earlier terminated, or extended in accordance with Section 3.1.1.
Appears in 3 contracts
Sources: Product Development and Commercialization Agreement, Product Development and Commercialization Agreement (ChemoCentryx, Inc.), Product Development and Commercialization Agreement (ChemoCentryx, Inc.)